Loading
BrightPath Biotherapeutics Co., Ltd. Stock: price and insider trades · Japan
ブライトパス・バイオ
JP·Mcap JP¥6.5B
BrightPath Biotherapeutics Co., Ltd.: what insiders have been doing
BrightPath Biotherapeutics Co., Ltd. is a listed company. Filings by its managers are published through EDINET (Japan FSA). In the past year (19 October 2025 to 19 October 2026), 9 filings came from 3 insiders.
No open-market purchase or sale appears among the filings, only grants, plan transactions and other operations. Because grants and exercises are largely decided by remuneration plans, they are not counted as purchases here.
Across the 3,423 companies tracked on its exchange, the median is 3 filings; at 9 filings, this issuer sits above that mark.
Over the last twelve months, not one insider purchase of BrightPath Biotherapeutics Co., Ltd. stock was filed. Filings reach the EDINET (Japan FSA) feed a median of 1 day after the trade. Until a filing is published, the market cannot know about the trade.
Source: insider filings from EDINET (Japan FSA). Past trades are no guide to future returns.
Insider Decl.
9
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
n/a
n/a
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 20,009 of 23,525 companies
26.7
score / 100
Value10
Quality44
FCF yld-21%
Earn yld-20%
EV/EBITDA·
ROE-79%
Gross mgn64%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2026FY ended March 2026 · cache
JP¥47
Analyst consensus
Income statement
RevenueJP¥84k
Gross profitJP¥54k64% margin
EBITDA-JP¥1.3B-1541668% margin
Net income-JP¥1.3B-1553513.1% margin
Valuation
P/Book4.8x
Balance sheet & cash
Market capJP¥6.5B
Free Cash Flow-JP¥1.4B
Profitability & ownership
ROE-79.2%
ROA-43.5%
% insiders3.9%
% institutions20.3%
Last declaration on 7 October 2026
Declarations9 total
100.0% of flowShareXTKSEDINET:S100Z6U2
6.7% of flowShareXTKSEDINET:S100XIMC
8.7% of flowShareXTKSEDINET:S100XGZJ
10.1% of flowShareXTKSEDINET:S100XGMY
13.1% of flowShareXTKSEDINET:S100XE6W
30.0% of flowShareXTKSEDINET:S100XEAU
31.3% of flowShareXTKSEDINET:S100XCPG
49.6% of flowShareXTKSEDINET:S100XBC0
50.4% of flowShareXTKSEDINET:S100XBBX
9 of 9 declarations
About BrightPath Biotherapeutics Co., Ltd.
BrightPath Bio is a company focused on developing innovative therapies in biotechnology. It is listed on the XTKS market.